Table 3. Incidence of recorded neuromuscular disease in the UK between 2015–2019.
| Classification | Total new cases | All (95% CI) | Females (95%CI) | Males (95%CI) |
|---|---|---|---|---|
| Motor Neuron Disorders | ||||
| • Motor neurone disease (MND) | 2,091 | 3.43 (3.29–3.58) | 2.91 (2.71–3.10) | 3.96 (3.74–4.19) |
| • Post polio syndrome | 77 | 0.13 (0.10–0.15) | 0.12 (0.08–0.16) | 0.13 (0.09–0.17) |
| • Spinal muscular atrophy | 118 | 0.19 (0.16–0.23) | 0.17 (0.12–0.22) | 0.22 (0.16–0.27) |
| Muscle Disease | ||||
| Acquired myopathies | ||||
| • Endocrine myopathy | 8 | 0.01 (0.00–0.02) | 0.02 (0.00–0.03) | 0.01 (0.00–0.02) |
| • Infectious myopathy | 127 | 0.21 (0.17–0.24) | 0.17 (0.12–0.22) | 0.25 (0.19–0.30) |
| • Inflammatory myopathies (IIM) | 790 | 1.30 (1.21–1.39) | 1.61 (1.47–1.75) | 0.98 (0.87–1.10) |
| • Toxic or drug-induced myopathy | 127 | 0.21 (0.17–0.24) | 0.15 (0.11–0.20) | 0.26 (0.21–0.32) |
| Hereditary myopathies | ||||
| • Congenital myopathy | 127 | 0.21 (0.17–0.24) | 0.23 (0.17–0.28) | 0.19 (0.14–0.24) |
| • Metabolic myopathies | 147 | 0.24 (0.20–0.28) | 0.19 (0.14–0.24) | 0.30 (0.24–0.36) |
| • Muscular dystrophy (MD) | 705 | 1.16 (1.07–1.24) | 0.89 (0.79–1.00) | 1.43 (1.29–1.56) |
| Other | ||||
| • Mitochondrial disease | 178 | 0.29 (0.25–0.34) | 0.34 (0.28–0.41) | 0.24 (0.19–0.30) |
| • Myotonic disorders (non-dystrophic) | 73 | 0.12 (0.09–0.15) | 0.16 (0.11–0.20) | 0.08 (0.05–0.11) |
| • Myotonic disorders (unspecified) | 132 | 0.22 (0.18–0.25) | 0.23 (0.18–0.28) | 0.20 (0.15–0.25) |
| • Periodic paralysis | 23 | 0.04 (0.02–0.05) | 0.02 (0.00–0.03) | 0.06 (0.03–0.09) |
| Neuropathies | ||||
| Hereditary neuropathy | ||||
| • Charcot-Marie Tooth (CMT) | 879 | 1.44 (1.35–1.54) | 1.25 (1.13–1.38) | 1.64 (1.49–1.78) |
| • Other hereditary neuropathy | 13 | 0.02 (0.01–0.03) | 0.01 (0.00–0.03) | 0.03 (0.01–0.05) |
| Inflammatory & autoimmune neuropathies | ||||
| • Guillain-Barré syndrome (GBS) | 1,040 | 1.71 (1.60–1.81) | 1.39 (1.26–1.52) | 2.03 (1.87–2.19) |
| • Other inflammatory & autoimmune neuropathies | 429 | 0.70 (0.64–0.77) | 0.45 (0.38–0.53) | 0.96 (0.85–1.07) |
| Neuromuscular Junction Disorders | ||||
| • Eaton-Lambert syndrome | 21 | 0.03 (0.02–0.05) | 0.04 (0.02–0.06) | 0.03 (0.01–0.05) |
| • Myasthenia gravis (MG) | 1,501 | 2.46 (2.34–2.59) | 2.06 (1.90–2.22) | 2.87 (2.68–3.06) |
| • Other NMJ disorder‡ | 76 | 0.12 (0.10–0.15) | 0.11 (0.08–0.15) | 0.13 (0.09–0.18) |
| Muscular or neuromuscular disease unspecified* | 312 | 0.51 (0.46–0.57) | 0.47 (0.40–0.55) | 0.55 (0.47–0.63) |
| All Neuromuscular Disease | ||||
| • Any | 8,563 | 14.09 (13.79–14.38) | 12.35 (11.96–12.75) | 15.83 (15.38–16.28) |
| • Any, standardised to 2019 mid-year UK population estimates | 14.22 (13.92–14.53) | 12.47 (12.07–12.87) | 16.02 (15.57–16.47) |
Note: Rates are the estimated rate calculated from 2015–9 data per 100,000 person years. All neuromuscular disease is additionally age-sex standardised to ONS 2019 mid-year population estimates for the whole of the UK. Patients can belong to multiple categories except for “unspecified”, where they are only classified if no other appropriate classification was available. Denominators used were (Any of the Above): 60,790,383 (All), 30,475,599 (Females), 30,314,785 (Males).